RUcore: Rutgers University Community Repository
Dietary lutein modulates expression of prostate cancer biomarker genes in human prostate cancer cell line
Descriptive
TypeOfResource
Text
TitleInfo
(ID = T-1)
Title
Dietary lutein modulates expression of prostate cancer biomarker genes in human prostate cancer cell line
SubTitle
PartName
PartNumber
NonSort
Identifier
ETD_1386
Identifier
(type = hdl)
http://hdl.rutgers.edu/1782.2/rucore10001600001.ETD.000050512
Language
(objectPart = )
LanguageTerm
(authority = ISO639-2);
(type = code)
eng
Genre
(authority = marcgt)
theses
Subject
(ID = SBJ-1);
(authority = RUETD)
Topic
Food Science
Subject
(ID = SBJ-2);
(authority = ETD-LCSH)
Topic
Carotenoids--Physiological effect
Subject
(ID = SBJ-3);
(authority = ETD-LCSH)
Topic
Prostate--Cancer
Subject
(ID = SBJ-4);
(authority = ETD-LCSH)
Topic
Cancer--Chemoprevention
Subject
(ID = SBJ-5);
(authority = ETD-LCSH)
Topic
Cancer--Diet therapy
Abstract
Prostate cancer is the second leading cause of death from malignancies in men and is the most commonly diagnosed cancer in the United States. Epidemiological studies have shown the inverse relationship between consumption of various carotenoids and the risk of prostate cancer. Lutein is a fat-soluble, oxycarotenoid present in human serum and is also present in the liver, colon, lung and prostate tissues. Lutein is not synthesized by the human body and is primarily consumed from dark-green leafy vegetables such as kale and spinach, as well as from egg yolks, avocado, corn and fruits like orange and kiwi. Lutein has gained popularity through its role in preventing age-related macular degeneration (AMD). Anti-inflammatory activity of lutein has also been the focus of a number of in vitro and in vivo studies. Recently much attention has focused on the role of lutein against various cancers including prostate cancer, however no mechanism of action was determined.
Our objective is to determine whether lutein modulates prostate cancer biomarker genes in hormone refractory prostate cancer (PC-3) cell lines using Oligo GEArray® DNA Microarray, which contains 263 genes involved in the progression and diagnosis of prostate cancer. PC-3 cells were treated with 10 μM non-toxic concentrations of lutein as determined by MTT cell viability assay. Isolated RNA was reverse-transcribed to cDNA, transcribed to cRNA and hybridized with microarrays. Microarray results demonstrated the down-regulation of epidermal growth factor receptor (EGFR), insulin-like growth factor 1 receptor (IGF1R), breast cancer gene 1 (BRCA1), cyclin dependant kinase 5 (CDK5), kallikrein 14 (KLK14) and prostate cancer antigen 3 (PCA3). Microarray results also showed the up-regulation of ras association domain family member 1 (RASSF1) and glutathione S-transferase pi 1 (GSTP1). Modulated genes were validated by Real-Time PCR and demonstrated down-regulation of IGF1R, EGFR, BRCA1, CDK5, KLK14 and PCA3 by 83%, 60%, 50%, 44%, 41% and 40% respectively. Similarly, up-regulated genes were also validated by Real-Time PCR and results showed GSTP1 and RASSF1 up-regulated by 82% and 70%. Modulated genes were further analyzed at the translational level using Western Blot. Among all the prostate cancer biomarker genes, IGF1R, EGFR and GSTP1 were most significantly modulated in Real-Time PCR analysis. Western blot analysis demonstrated that lutein treatment down-regulated the protein expression of IGF1R and EGFR by 40.4% and 33.1% while up-regulating GSTP1 by 30.0%. These results demonstrate the potential of lutein to modulate a number of key biomarker genes involved in human prostate cancer proliferation, differentiation, angiogenesis and apoptosis.
Our objective is to determine whether lutein modulates prostate cancer biomarker genes in hormone refractory prostate cancer (PC-3) cell lines using Oligo GEArray® DNA Microarray, which contains 263 genes involved in the progression and diagnosis of prostate cancer. PC-3 cells were treated with 10 μM non-toxic concentrations of lutein as determined by MTT cell viability assay. Isolated RNA was reverse-transcribed to cDNA, transcribed to cRNA and hybridized with microarrays. Microarray results demonstrated the down-regulation of epidermal growth factor receptor (EGFR), insulin-like growth factor 1 receptor (IGF1R), breast cancer gene 1 (BRCA1), cyclin dependant kinase 5 (CDK5), kallikrein 14 (KLK14) and prostate cancer antigen 3 (PCA3). Microarray results also showed the up-regulation of ras association domain family member 1 (RASSF1) and glutathione S-transferase pi 1 (GSTP1). Modulated genes were validated by Real-Time PCR and demonstrated down-regulation of IGF1R, EGFR, BRCA1, CDK5, KLK14 and PCA3 by 83%, 60%, 50%, 44%, 41% and 40% respectively. Similarly, up-regulated genes were also validated by Real-Time PCR and results showed GSTP1 and RASSF1 up-regulated by 82% and 70%. Modulated genes were further analyzed at the translational level using Western Blot. Among all the prostate cancer biomarker genes, IGF1R, EGFR and GSTP1 were most significantly modulated in Real-Time PCR analysis. Western blot analysis demonstrated that lutein treatment down-regulated the protein expression of IGF1R and EGFR by 40.4% and 33.1% while up-regulating GSTP1 by 30.0%. These results demonstrate the potential of lutein to modulate a number of key biomarker genes involved in human prostate cancer proliferation, differentiation, angiogenesis and apoptosis.
PhysicalDescription
Form
(authority = gmd)
electronic resource
Extent
xi, 87 p.
InternetMediaType
application/pdf
InternetMediaType
text/xml
Note
(type = degree)
M.S.
Note
(type = bibliography)
Includes bibliographical references (p. 66-74)
Note
(type = statement of responsibility)
by Sarita V. Gokarn
Name
(ID = NAME-1);
(type = personal)
NamePart
(type = family)
Gokarn
NamePart
(type = given)
Sarita V.
Role
RoleTerm
(authority = RULIB);
(type = )
author
DisplayForm
Sarita V. Gokarn
Name
(ID = NAME-2);
(type = personal)
NamePart
(type = family)
Rafi
NamePart
(type = given)
Mohammed
Role
RoleTerm
(authority = RULIB);
(type = )
chair
Affiliation
Advisory Committee
DisplayForm
Mohammed M Rafi
Name
(ID = NAME-3);
(type = personal)
NamePart
(type = family)
Lachance
NamePart
(type = given)
Paul
Role
RoleTerm
(authority = RULIB);
(type = )
internal member
Affiliation
Advisory Committee
DisplayForm
Paul Lachance
Name
(ID = NAME-4);
(type = personal)
NamePart
(type = family)
Daun
NamePart
(type = given)
Henryk
Role
RoleTerm
(authority = RULIB);
(type = )
internal member
Affiliation
Advisory Committee
DisplayForm
Henryk Daun
Name
(ID = NAME-1);
(type = corporate)
NamePart
Rutgers University
Role
RoleTerm
(authority = RULIB);
(type = )
degree grantor
Name
(ID = NAME-2);
(type = corporate)
NamePart
Graduate School - New Brunswick
Role
RoleTerm
(authority = RULIB);
(type = )
school
OriginInfo
DateCreated
(point = );
(qualifier = exact)
2009
DateOther
(qualifier = exact);
(type = degree)
2009-01
Place
PlaceTerm
(type = code)
xx
Location
PhysicalLocation
(authority = marcorg)
NjNbRU
RelatedItem
(type = host)
TitleInfo
Title
Rutgers University Electronic Theses and Dissertations
Identifier
(type = RULIB)
ETD
RelatedItem
(type = host)
TitleInfo
Title
Graduate School - New Brunswick Electronic Theses and Dissertations
Identifier
(type = local)
rucore19991600001
Identifier
(type = doi)
doi:10.7282/T3V1252X
Genre
(authority = ExL-Esploro)
ETD graduate
Back to the top
Rights
RightsDeclaration
(AUTHORITY = GS);
(ID = rulibRdec0006)
The author owns the copyright to this work.
Copyright
Status
Copyright protected
Availability
Status
Open
RightsEvent
(AUTHORITY = rulib);
(ID = 1)
Type
Permission or license
Detail
Non-exclusive ETD license
AssociatedObject
(AUTHORITY = rulib);
(ID = 1)
Type
License
Name
Author Agreement License
Detail
I hereby grant to the Rutgers University Libraries and to my school the non-exclusive right to archive, reproduce and distribute my thesis or dissertation, in whole or in part, and/or my abstract, in whole or in part, in and from an electronic format, subject to the release date subsequently stipulated in this submittal form and approved by my school. I represent and stipulate that the thesis or dissertation and its abstract are my original work, that they do not infringe or violate any rights of others, and that I make these grants as the sole owner of the rights to my thesis or dissertation and its abstract. I represent that I have obtained written permissions, when necessary, from the owner(s) of each third party copyrighted matter to be included in my thesis or dissertation and will supply copies of such upon request by my school. I acknowledge that RU ETD and my school will not distribute my thesis or dissertation or its abstract if, in their reasonable judgment, they believe all such rights have not been secured. I acknowledge that I retain ownership rights to the copyright of my work. I also retain the right to use all or part of this thesis or dissertation in future works, such as articles or books.
Back to the top
Technical
ContentModel
ETD
MimeType
(TYPE = file)
application/pdf
MimeType
(TYPE = container)
application/x-tar
FileSize
(UNIT = bytes)
901120
Checksum
(METHOD = SHA1)
aa76bdf87d30e6bc36d7f849bb9186566869f99f
Back to the top
Statistical Profile